Results 161 to 170 of about 26,674 (238)

Subcutaneous Abatacept in New Onset Type 1 Diabetes: Clinical and Immunological Effects. [PDF]

Diabetes Metab Res Rev
Jerram ST, Yang JHM, Williams E, Domingo-Vila C, Liu YF, Peakman M, Leslie RD, Tree T.   +7 more
europepmc   +1 more source

Neuroinflammation in CTLA-4 Haploinsufficiency: Case Report of a New Variant with Remarkable Response to Targeted Therapy. [PDF]

Int J Mol Sci
Baldini L, Del Vecchio L, Cerasi S, Fetta A, Moratti M, Bezzi A, Ferrari S, Di Dalmazi G, Rossi S, Toni F, Cordelli DM, Lanari M, Conti F.   +12 more
europepmc   +1 more source

FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD. [PDF]

Clin Cancer Res
Norsworthy KJ, Rivera DR, Wynne J, Zhao J, Konicki R, Kuzucan A, Vallejo J, Leong R, Okusanya OO, Booth B, Kluetz PG, Pazdur R, de Claro RA.   +12 more
europepmc   +1 more source

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019

, 2020
Bathon, J., Breedveld, F., Burmester, G., Bykerk, V., Crofford, L., Cronstein, B., Dougados, M., Furst, D., Kalden, J., Mariette, X., Mease, P., Melchers, F., Rosenbaum, J., Sieper, J., Smolen, J., Weinblatt, M., Winthrop, K.   +16 more
core   +1 more source

A Randomized, Double-Blind, Placebo-Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis. [PDF]

Arthritis Rheumatol
Langford CA, Khalidi N, Springer J, Friedman M, Hellmich B, Pagnoux C, Dehghan N, Gewurz-Singer O, Koening CL, Lin YC, Monach PA, Moreland LW, Fifi-Mah A, Flossmann O, Forbess LJ, Lanyon P, Molloy E, Specks U, Spiera R, Yacyshyn E, McAlear CA, Burroughs C, Jones RB, Rhee RL, Hajj-Ali R, Warrington KJ, Cuthbertson D, Krischer JP, Jayne D, Merkel PA, Vasculitis Clinical Research Consortium and the European Vasculitis Society.   +30 more
europepmc   +1 more source

How should immune checkpoint inhibitor myocarditis be treated? [PDF]

Cardiooncology
Badaan S, Abbass A, Tov S, Bar-Sela G, Bisharat N.   +4 more
europepmc   +1 more source

Targeted Therapy for Idiopathic Inflammatory Myopathy. [PDF]

J Cachexia Sarcopenia Muscle
Wang R, Lin W, Xie Q, Yin G.
europepmc   +1 more source

The "Clinical Topics" from the Electronic Health Record of Patients with Rheumatoid Arthritis Before Initiating Targeted Therapies and Association with Future Treatment Course. [PDF]

ACR Open Rheumatol
Tang J, Weisenfeld D, Wang L, Jeffway M, Cagan A, Bonzel CL, McDermott GC, Cai T, Liao KP.   +8 more
europepmc   +1 more source

A tocilizumab (RoActemra®) szerepe a rheumatoid arthritis terápiájában - szakirodalmi áttekintés és egészség-gazdaságtani vizsgálat = Tocilizumab (RoActemra®) in patients with rheumatoid arthritis: systematic review and health economic evaluation – Health Technology Assessment Report [PDF]

, 2009
Brodszky, Valentin, Gulácsi, László, Péntek, Márta, Érsek, Katalin   +3 more
core  

Non-TNF-targeted drugs in rheumatic diseasescombined with latent tuberculosis infection. [PDF]

Clin Exp Med
Xiang Z, Liuyu, Zou H.
europepmc   +1 more source